These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31795821)

  • 41. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis.
    Gutiérrez-García G; Cibeira MT; Rovira M; Fernández de Larrea C; Tovar N; Rodríguez-Lobato LG; Rosiñol L; Marín P; Solano-Vega J; Suárez-Lledó M; Bataller A; Solano MT; de Llobet N; Domenech A; Borràs N; Lozano M; Cid J; Martínez C; Urbano-Ispizua Á; Esteve J; Carreras E; Fernández-Avilés F; Bladé J
    Bone Marrow Transplant; 2019 Aug; 54(8):1295-1303. PubMed ID: 30664727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.
    Tovar N; Cibeira MT; Rosiñol L; Solé M; de Larrea CF; Escoda L; Rovira M; Bladé J
    Eur J Haematol; 2012 Oct; 89(4):340-4. PubMed ID: 22690902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autologous Stem Cell Transplant in Hodgkin's and Non-Hodgkin's Lymphoma, Multiple Myeloma, and AL Amyloidosis.
    Alnasser SM; Alharbi KS; Almutairy AF; Almutairi SM; Alolayan AM
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132175
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.
    Sidana S; Sidiqi MH; Dispenzieri A; Buadi FK; Lacy MQ; Muchtar E; Dingli D; Hayman SR; Gonsalves WI; Kapoor P; Leung N; Warsame R; Kourelis TV; Wolf RC; Hogan WJ; Kumar SK; Gertz MA
    Am J Hematol; 2019 Sep; 94(9):1020-1026. PubMed ID: 31254301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
    Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.
    Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M
    Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea.
    Kim SJ; Lee GY; Jang HR; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
    Amyloid; 2013 Dec; 20(4):204-11. PubMed ID: 23914780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical characteristics and prognosis of a Chinese cohort with systemic light chain amyloidosis: a single-center study.
    Xie W; Wang Q; Zhou F; Wang S; Sun Y; Cen X; Ren H; Qiu Z; Dong Y
    Int J Hematol; 2023 Aug; 118(2):231-241. PubMed ID: 37247070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions.
    Alsomali D; Mohty D; Grogan M; Dispenzieri A; Aljurf M; Kumar S; Gertz MA; Hanbali A; Hashmi SK
    Clin Adv Hematol Oncol; 2022 Oct; 20(10):609-618. PubMed ID: 36206073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients].
    Adam Z; Ozábalová E; Němec P; Bedáňová H; Kuman M; Krejčí J; Špinarová L; Žampachová V; Čermáková Z; Pour L; Krejčí M; Sanecká V; Štork M; Pika T; Straub J; Adamová D; Stavařová Y; Král Z; Mayer J
    Vnitr Lek; 2018; 64(4):441-449. PubMed ID: 29791180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Autologous peripheral blood hematopoietic stem cell transplantation for patients with primary light chain amyloidosis: experience of 31 cases in a single center].
    Li J; Feng J; Cao XX; Zhang CL; Shen KN; Huang XF; Zhang CL; Duan MH; Zhang W; Zhu TN; Cai HC; Zhang L; Cai H; Zhou DB
    Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):201-4. PubMed ID: 27033756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients.
    Lisenko K; Wuchter P; Hansberg M; Mangatter A; Benner A; Ho AD; Goldschmidt H; Hegenbart U; Schönland S
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1870-1878. PubMed ID: 28754546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.
    Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Dingli D; Buadi FK; Grogan M; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Dispenzieri A
    Blood; 2017 Apr; 129(15):2111-2119. PubMed ID: 28126928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Light Chain Amyloidosis: an Update for Treatment].
    Shen KN; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):910-4. PubMed ID: 26117060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 57. Characteristics of Engraftment Syndrome following Autologous Stem Cell Transplantation in Light Chain Amyloidosis with Renal Involvement.
    Miao F; Ren G; Guo J; Zhao L; Xu W; Huang X
    Transplant Cell Ther; 2023 Feb; 29(2):110.e1-110.e8. PubMed ID: 36323398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiac and renal AL amyloidosis controlled by autologous stem cell transplantation for 17 years accompanying late onset atrial fibrillation and complete atrioventricular block.
    Iijima T; Sawa N; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Ubara Y; Ohashi K
    CEN Case Rep; 2023 Nov; 12(4):362-367. PubMed ID: 36795309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis).
    Chaulagain CP; Herlitz LC; Fu J; Bilani N; Lucitt C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e826-e831. PubMed ID: 32703752
    [No Abstract]   [Full Text] [Related]  

  • 60. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.